Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1238 • ACR Convergence 2021
Low Patient Global Assessment of Disease Activity and Negative Rheumatoid Factor Are Strongly Associated with Likelihood of Maintaining Remission Following Tapering of Therapy in Patients with Rheumatoid Arthritis
Jeffrey Curtis¹, Paul Emery², Boulos Haraoui³, Greg Kricorian⁴, Priscilla Yen⁴, David Collier⁵ and Vivian Bykerk⁶, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Inc., Simi Valley, CA, ⁶Hospital for Special Surgery, New York, NY
Background/Purpose: According to ACR and EULAR recommendations, patients with rheumatoid arthritis (RA) who persist in remission (REM) should consider tapering RA therapy. Identification of clinical…
Abstract Number: 1254 • ACR Convergence 2021
The Role of Regulatory T Cells (CD4+CD25+FOXP3) in Methotrexate Unresponsiveness in a Cohort of Naive Rheumatoid Arthritis Patients
Anna Abou-Raya, Darwish ELHallous, Mohamed Ossama, Nahla Farahat, Mohamed Khaled and Suzan Abou-Raya, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic immune-mediated heterogenous disease characterized by a defect in the compartment of regulatory CD4+Foxp3+ T cells (Treg) which are…
Abstract Number: 1508 • ACR Convergence 2021
Decrease of Angiogenic T Cells Associated to the Presence of Interstitial Lung Disease in Patients with Connective Tissue Diseases
Verónica Pulito-Cueto¹, Sara Remuzgo-Martinez¹, Fernanda Genre¹, Belén Atienza-Mateo², Victor M. Mora-Cuesta³, David Iturbe-Fernández³, Leticia Lera-Gómez¹, Raquel Perez-Fernández¹, Pilar Alonso-Lecue⁴, Javier Rodriguez-Carrio⁵, Diana Prieto-Peña⁶, Virginia Portilla⁶, Ricardo BLANCO⁷, Alfosno Corrales⁶, José M. Cifrián⁸, Raquel López-Mejías¹ and Miguel Ángel gonzalez-Gay⁹, ¹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System; Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Deparment of Functional Biology, Immunology Area, Faculty of Medicine, Universidad de Oviedo, Oviedo, Asturias, Spain., Oviedo, Spain, ⁶Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Hospital University Marqués de Valdecilla, Santander, Spain, ⁸Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; Department of Pneumology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain, ⁹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Interstitial lung disease (ILD) is one of the most significant complications of connective tissue diseases (CTD) leading to an increase of the morbidity and…
Abstract Number: 1653 • ACR Convergence 2021
Positron Emission Tomography-Detected Uptake of 18F-Fluorodeoxyglucose in Visceral and Subcutaneous Adipose Tissue Is Associated with Articular Disease Activity and Arterial Inflammation in Rheumatoid Arthritis
Jon Giles¹, Joan Bathon², Hadil Zureigat³ and Ahmed Tawakol⁴, ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²Columbia University, New York, NY, ³Harvard University, Boston, MA, ⁴Harvard University/Massachusetts General Hospital, Boston, MA
Background/Purpose: Subcutaneous adipose tissue (SAT) from people with RA contains more macrophages and expresses higher levels of cytokines, chemokines, and other inflammatory mediators compared with…
Abstract Number: 1669 • ACR Convergence 2021
Minimal Erosive Volume Needed for Radiographic Identification of Erosions in the Metacarpophalangeal Joints in Rheumatoid Arthritis. a Comparative Analysis of High Resolution Peripheral Quantitative Computed Tomography and Conventional Radiography
Rasmus Klose-Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, Bente L. Langdahl, Anna Zejden, Jesper Thygensen, Kresten Krarup Keller and Ellen-Margrethe Hauge, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The purpose of this study was to estimate the minimal erosive volume identified by High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT) needed in order to…
Abstract Number: 1685 • ACR Convergence 2021
Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – Placebo and Active Controlled Study
Eugen Feist¹, Saeed Fatenejad², Sergey Grishin³, Elena Korneva³, Evgeniy Nasonov⁴, Anna Rowińska-Osuch⁵, Mikhail Samsonov⁶ and Roy Fleischmann⁷, ¹Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ²SFC Medica, LLC, Charlotte, NC, ³R-Pharm, Moscow, Russia, ⁴V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, ⁵MCM Polimedica, Warsaw, Poland, ⁶RPharm, Moscow, Russia, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Olokizumab (OKZ) is a humanized monoclonal antibody targeting IL-6 [1]. Here we present the results of a global phase III, head-to-head, randomized placebo (PBO)…
Abstract Number: 1701 • ACR Convergence 2021
Evaluation of Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis Patients, Treated with Biological Agents: 6-month Follow-up
Georgios Papamichail¹, Theodora Markatseli², Athanasios Georgiadis³, Vasileios Xydis⁴, Haralampos Milionis¹, Alexandros Drosos² and Paraskevi Voulgari², ¹Internal Medicine, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ²Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ³Private Practice, Ioannina, Greece, Athens, Greece, ⁴Radiology, Department of Radiology, Medical School, University of Ioannina, Ioannina, Greece, Ioannina, Greece
Background/Purpose: Despite new therapeutic approaches in RA, the mortality gap between RA patients and the general population persists, and may even be increasing. Cardiovascular (CV)…
Abstract Number: 1909 • ACR Convergence 2021
Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
Md Rashedul Hoque¹, J. Antonio Avina-Zubieta², Diane Lacaille², Mary De Vera³, Yi Qian³, John Esdaile⁴ and Hui Xie⁵, ¹Simon Fraser University, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: Literature has shown poor adherence to antimalarial (AM) medications in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients, with the percentage of adherers…
Abstract Number: PP08 • ACR Convergence 2021
Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making
Aberdeen Allen, Colgate Palmolive, Parlin, NJ
Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
Abstract Number: L04 • ACR Convergence 2020
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
Kevin L Winthrop¹, Arne Yndestad², Dan Henrohn³, Hyejin Jo⁴, Sara Marsal⁵, Maria Galindo⁶, Annette Diehl⁷, Andrea B Shapiro⁸ and Stanley B Cohen⁹, ¹Oregon Health & Science University, Portland, OR, ²Pfizer Inc, Oslo, Norway, ³Pfizer Inc, Sollentuna, Sweden, ⁴Syneos Health, Raleigh, NC, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Rheumatology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Patients (pts) with RA have increased susceptibility to seasonal influenza and its complications.1 The COVID-19 pandemic highlights the need to understand acute respiratory RNA…
Abstract Number: 0032 • ACR Convergence 2020
A Prospective, Multicenter, Clinical Performance Evaluation Study for an in-vitro Diagnostics Medical Device (PREDYSTIC® Infliximab RA) for Prediction of Infliximab Responsiveness in the Treatment of Rheumatoid Arthritis
Miklos Sebeszta¹, Katalin Tauberne Jakab¹, Tamas Ponyi¹, Gyula Poor², Zsolt Hollo¹, Laszlo Szilagyi¹, Emese Kiss² and Gabor Zahuczky³, ¹Egis Pharmaceuticals, Budapest, Hungary, ²ORFI, Budapest, Hungary, ³UD Genomed, Debrecen, Hungary
Background/Purpose: Approximately 30-40% of RA patients fail to respond to first biological therapy. Predicting the patient’s responsiveness to the first biological therapy is still an…
Abstract Number: 0104 • ACR Convergence 2020
Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis
Attila Hamar¹, Anita Pusztai², Edit Végh¹, Ágnes Horváth¹, Katalin Gulyás¹, Szilvia Szamosi¹, Zsófia Pethő¹, Nóra Bodnár¹, Boglárka Soós¹, Monika Czókolyová¹, Sándor Szántó¹, Gabriella Szűcs¹, Harjit Bhattoa¹, Gábor Nagy¹, Gábor Tajti¹, Andrea Domján¹, Katalin Hodosi¹ and Zoltán Szekanecz¹, ¹University of Debrecen, Debrecen, Hungary, ²University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary
Background/Purpose: Oral JAK inhibitor, tofacitinib appeared as a new therapeutic option, beside biological therapies, which has already proven its safety and effectivity in RA, but…
Abstract Number: 0149 • ACR Convergence 2020
How Stable Are Medication Necessity Beliefs and Safety Concerns in the First Year of RA?
Viviane Ta¹, Orit Schieir², Marie-France Valois³, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet Pope⁹, Carter Thorne¹⁰, Diane Tin¹⁰, Nicole Andersen¹, Vivian Bykerk¹¹, Susan Bartlett³ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹McGill University, Montreal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec, Canada, ⁵Universite de Sherbrooke, Sherbrooke, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, ⁹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: At RA onset, DMARDs are essential to controlling inflammation and preventing disability. In people with established RA, specific beliefs about the necessity of DMARDs…
Abstract Number: 0186 • ACR Convergence 2020
The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
Magali Zanotti-Cavazzoni¹ and Gabriela Avila², ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Sociedad Paraguaya de Reumatologia, Asuncion, Paraguay
Background/Purpose: Disease activity scores (DAS) are used as tools to assess persistent inflammation and need for therapeutic escalation in patients with Rheumatoid arthritis (RA). One…
Abstract Number: 0202 • ACR Convergence 2020
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis
Kevin Winthrop¹, Tsutomu Takeuchi², Gerd Burmester³, Patrick Durez⁴, Walter Deberdt⁵, Douglas Schlichting⁶, Scott Beattie⁶, Daojun Mo⁷, Chad Walls⁶ and Josef Smolen⁸, ¹Oregon Health & Science University, Portland, OR, ²Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ³Charité University Hospital Berlin, Berlin, Germany, ⁴Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁵Eli Lilly and Company, Brussels, Belgium, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Carmel, IN, ⁸Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK)1/JAK 2 inhibitor approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].